Shots:

• MiNA and AstraZeneca will conduct in vitro and in vivo studies allowing the development of saRNA therapies for Metabolic Diseases. Post the completion of the studies- AstraZeneca will have an option to further develop saRNA therapies for its identified targets
• The focus of the collaboration is to combine MiNA's expertise in the discovery and development of saRNA therapies with AZ’s insights of identifying and developing breakthrough therapies for metabolic diseases
• Small activating RNA (saRNAs) are therapies involved in modality to upregulate genes with the capability to access disease-relevant targets

Click here to read full press release/ article

Ref: MiNA Therapeutics | Image: Signbox